S&P 500 Industrials Sector SEC Filings — March 19, 2026

19-03-2026

Eledon Pharmaceuticals reported FY2025 net loss of $45.6M, up from $36.2M in FY2024, driven by a 27.5% increase in R&D expenses to $66.3M due to clinical advancements, though G&A expenses declined 8.7% to $17.0M. Positive clinical updates include 24-month Phase 1b data showing improved eGFR (67.0 to 74.2 mL/min/1.73 m²) with no rejections in kidney transplant patients and 100% insulin independence in 10 type 1 diabetes patients on tegoprubart post-islet transplant; tegoprubart also received FDA Orphan Drug designation for liver transplantation. Cash and equivalents rose to $22.8M, with total current assets at $135.7M despite a decline from $143.7M prior year.

• ·No episodes of biopsy-proven acute rejection, graft loss, death, new-onset diabetes mellitus, or de novo donor-specific antibody formation in Phase 1b kidney transplant study.
• ·Mean most recent HbA1c of approximately 5.35% in 10 insulin-independent type 1 diabetes patients.
• ·Warrant liabilities decreased to $11.4M from $44.9M.
• ·Adjusted net loss excluding warrant changes: $79.1M in FY2025 vs $67.1M in FY2024.
• ·Basic EPS: $(0.52) FY2025 vs $(0.66) FY2024.

19-03-2026

UPS filed its DEF 14A Proxy Statement on March 19, 2026, for the 2026 Annual Meeting of Shareowners, proposing the election of directors including Carol Tome, Brian Dykes, Nando Cesarone, Kate Gutmann, and Bala Subramanian (terms expiring May 9, 2025), an advisory vote on 2025 Named Executive Officer compensation, approval of the 2026 Omnibus Incentive Compensation Plan, ratification of auditors, and responses to shareowner proposals on Class A voting power reduction and community impact reporting. The Board Chair letter notes 2025 as a pivotal year marked by a strategic shift to reduce non-value volume from the largest customer to prioritize high-value growth capacity. No specific compensation amounts or period-over-period changes are detailed in the provided filing excerpt.

• ·Proxy items include Proposal 5: Shareowner proposal to reduce Class A stock voting power from 10 to 1 vote per share.
• ·Proposal 6: Shareowner proposal for independent evaluation of UPS operations' impacts on BIPOC and low-income communities.
• ·Proposal 7: Shareowner proposal for report on aligning operations with carbon neutrality goal.
• ·Compensation disclosures cover 2021-2025 periods for PEO and Non-PEO NEOs, including equity awards, pension changes, and pay versus performance.

19-03-2026

Bancroft Fund Ltd. has issued a proxy statement for its Annual Meeting of Shareholders on May 11, 2026, at 8:00 a.m. ET, to elect four Trustees: three (Kinchen C. Bizzell, James P. Conn, Frank J. Fahrenkopf, Jr.) by common and preferred shareholders voting together as a single class, and one (Michael J. Melarkey) by preferred shareholders as a separate class. The record date is March 12, 2026, with 5,822,431 common shares and 1,098,623 preferred shares outstanding. Major shareholders owning 5% or more include Saba Capital Management, L.P. (6.2% of common shares), Ameriprise Financial Inc. (5.2% of common shares), and Americo Investment Advisors Inc. (5.5% of preferred shares).

• ·Quorum requires holders of one-third of outstanding shares entitled to vote
• ·Preferred shareholders elect one Trustee (Michael J. Melarkey) as a separate class; three others jointly with common shareholders
• ·No dividend arrearages on Preferred Shares as of proxy date
• ·Fiscal year ended September 30, 2025
• ·Meeting location: Indian Harbor Yacht Club, 710 Steamboat Road, Greenwich, Connecticut, 06830
• ·Proxy materials mailed on or about April 1, 2026

19-03-2026

The GDL Fund (GDL) filed a DEFA14A on March 19, 2026, consisting of definitive additional proxy materials pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing includes standard checkboxes indicating no fee required and is filed by the registrant. No specific proxy matters, financial data, or substantive details are disclosed in the provided excerpt.

19-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 19, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'AITX's RAD Books Hundreds of SARA Licenses as Customers Expand After Initial Deployment.' The press release is furnished as Exhibit 99.1 and is not deemed filed or material.

• ·Filed by newsfilecorp.com
• ·Registrant details: Nevada incorporation, Commission File Number 000-55079, IRS Employer Identification No. 27-2343603, principal offices at 10800 Galaxie Avenue, Ferndale, Michigan 48220

19-03-2026

Legence Corp. filed Amendment No. 1 to its January 2, 2026 Form 8-K to include the required audited consolidated financial statements of acquired business The Bowers Group, Inc. (Bowers) for the year ended September 30, 2025 (Exhibit 99.1), and unaudited pro forma condensed combined financial information for Legence and subsidiaries as of September 30, 2025, for the nine months ended September 30, 2025, and the year ended December 31, 2024 (Exhibit 99.2). The acquisition of 100% of Bowers' equity interests was consummated on January 2, 2026, via Legence Corp. and its subsidiary Legence Subsidiary Holdings, LLC. No specific financial metrics or performance changes are disclosed in the filing text.

• ·Auditor consent for Bowers financials provided by Lanigan Ryan, P.C. (Exhibit 23.1)
• ·Securities: Class A common stock (LGN) on Nasdaq Stock Market LLC
• ·Company headquarters: 1601 Las Plumas Avenue, San Jose, CA 95133

19-03-2026

Catalyst Pharmaceuticals, Inc. (CPRX) filed an 8-K/A on March 19, 2026, to correct a scrivener’s error in the signature date of its prior 8-K filed on March 18, 2026. The underlying event discloses a District Court for the District of New Jersey order delaying the bench trial against Hetero USA, Inc. from March 23, 2026, to May 18, 2026, concerning the validity of the company's Orange Book-listed patents for FIRDAPSE® that expire in 2032, 2034, and 2037. No other changes were made to the original filing.

• ·District Court for the District of New Jersey issued the trial delay order.
• ·Patents are Orange Book-listed.

19-03-2026

Global Net Lease, Inc. announced the declaration of quarterly dividends on its preferred stocks on March 19, 2026: $0.453125 per share for 7.25% Series A, $0.4296875 per share for 6.875% Series B, $0.46875 per share for 7.50% Series D, and $0.4609375 per share for 7.375% Series E, all payable on April 15, 2026 to holders of record on April 3, 2026. These dividends align with the stated coupon rates, providing expected returns to preferred shareholders.

• ·All preferred stocks listed on New York Stock Exchange
• ·Company address: 650 Fifth Avenue, 30th Floor, New York, New York 10019
• ·Telephone: (332) 265-2020

19-03-2026

argenx SE reported robust 2025 financial results with product net sales surging 90% YoY to $4.15B from $2.19B, driving total operating income up 89% to $4.25B and flipping operating profit to $1.05B from a $22M loss. However, total operating expenses increased 40% to $3.19B due to cost of sales rising 98% to $451M, R&D up 39% to $1.36B, and SG&A up 30% to $1.37B; profit grew 55% to $1.29B but the income tax benefit dropped 98% to $13M. Basic EPS rose 51% to $21.08.

• ·2025 Remuneration Policy approved at approx. 96% vs 2021 policy at 77%.
• ·Non-Executive Director annual equity grant: $400,000 in restricted shares with 4-year holding.
• ·Shares outstanding grew from 59,194,488 (Dec 31, 2023) to 61,883,306 (Dec 31, 2025).

19-03-2026

United Bancorp, Inc. filed an amended Form 10-K/A for the fiscal year ended December 31, 2025, on March 19, 2026, primarily incorporating exhibits by reference including governance documents, executive change-in-control agreements, supplemental life insurance and deferred compensation plans, stock incentive plans, subordinated debt agreements, the 2025 Annual Report, insider trading policies, subsidiaries list, audit consents, and Sarbanes-Oxley certifications. Signatures were provided by CEO Scott A. Everson, CFO Randall M. Greenwood, and directors on March 18, 2026. No financial performance metrics, period-over-period comparisons, or material updates to results are detailed in the filing content.

• ·Filing covers FY 2025 (January 1, 2025 to December 31, 2025).
• ·Key exhibits include Clawback Policy (Exhibit 97) and Insider Trading Policies and Procedures (Exhibit 19).

19-03-2026

Darden Restaurants reported Q3 FY26 total sales up 5.9% YoY to $3.3B, driven by 4.2% blended same-restaurant sales growth, with LongHorn Steakhouse (+7.2%) and Other Business (+13.9%) leading, while Olive Garden (+3.2%) and Fine Dining (+2.1%) showed more modest gains; adjusted diluted EPS rose 5.4% to $2.95, though reported EPS declined to $2.68 from $2.74 amid closure costs and impairments. YTD segment profit for Fine Dining fell 3.1% to $174.1M despite overall YTD sales growth of 7.8% to $9.5B. The company repurchased $127M in stock, declared a $1.50 quarterly dividend, and updated FY26 outlook for ~9.5% sales growth and adjusted EPS of $10.57-$10.67.

• ·Q3 Olive Garden segment profit up 4.1% to $320M; LongHorn up 4.8% to $159M; Other Business up 3.1% to $108.8M.
• ·FY26 outlook includes ~2% sales growth from 53rd week and ~$0.25 EPS impact; effective tax rate ~12.5%; ~116.5M weighted average diluted shares.
• ·Quarterly dividend of $1.50 per share payable May 1, 2026 to shareholders of record April 10, 2026.
• ·Investor conference call held March 19, 2026 at 8:30am ET.

19-03-2026

Kolibri Global Energy Inc. (KGEI), a foreign private issuer and emerging growth company, filed its Form 40-F Annual Report for the fiscal year ended December 31, 2025, incorporating by reference its Annual Information Form (AIF), Management’s Discussion and Analysis (MD&A), and audited consolidated financial statements for 2025 and 2024 prepared under IFRS. The company reported 35,471,833 common shares outstanding as of December 31, 2025, with shares listed on Nasdaq Capital Market (KGEI) and Toronto Stock Exchange. Management certified effective disclosure controls and internal controls over financial reporting, with no material changes or errors noted.

• ·Audit committee financial expert: Doug Urch (independent).
• ·Principal executive offices: 925 Broadbeck Drive, Suite 220, Thousand Oaks, CA 91320.
• ·Shareholder special meeting on November 25, 2025, limited authorized common shares to 37,367,894 without approval.
• ·No off-balance sheet arrangements material to investors.
• ·No waivers to Code of Business Conduct and Ethics in 2025.

19-03-2026

DevvStream Corp. reduced outstanding debt by approximately $5.9 million net of a new $700,000 0% interest loan from Helena Partners, through Focus Impact Partners converting $5.5 million of 5.3% notes and fees into equity at a 12.9% premium, and prepaying $1.1 million to Helena from released $1.2 million collateral. These moves strengthen the balance sheet and signal partner confidence. However, forward-looking risks highlight potential insufficient liquidity from the new loan, Nasdaq delisting threats, and operational constraints from existing debt.

• ·FIP 5.3% convertible notes due November 2026
• ·Helena convertible note dated July 17, 2025
• ·Helena interest waiver through May 2026
• ·New Helena loan due March 2027
• ·Announcement date: March 13, 2026
• ·Filing date: March 19, 2026

19-03-2026

GE HealthCare Technologies Inc. (GEHC) issued a DEFA14A proxy notice for its 2026 Annual Meeting on May 7, 2026, at 8:00 a.m. Central Time, held virtually. Shareholders can vote on the election of eight director nominees, advisory approval of named executive officers' compensation, and ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026. Proxy materials are available online at www.proxyvote.com, with requests for paper/email copies due by April 23, 2026, and voting deadlines of May 6, 2026 (general) or May 1, 2026 (Sun Life plan).

• ·Voting at www.proxyvote.com or virtually at www.virtualshareholdermeeting.com/GEHC2026.
• ·Request materials via www.proxyvote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number).
• ·Company address: 500 W. Monroe Street, Chicago, IL 60661.

19-03-2026

Armata Pharmaceuticals, Inc. (ARMP) announced on March 19, 2026, that it will delay the release of its financial results for the fourth quarter and full year ended December 31, 2025, while furnishing a corporate update via press release (Exhibit 99.1). No preliminary financial metrics or details were provided in the filing. The delay may signal potential challenges, with no offsetting positive developments disclosed.

• ·Registrant details: Washington incorporation, Commission File Number 001-37544, IRS EIN 91-1549568, principal offices at 5005 McConnell Avenue, Los Angeles, CA 90066.
• ·Common Stock traded as ARMP on NYSE American.

19-03-2026

On March 19, 2026, the Board of Directors of SR Bancorp, Inc. (SRBK) declared a cash quarterly dividend of $0.05 per share. The dividend is payable on April 15, 2026, to stockholders of record as of March 31, 2026. No other financial metrics or comparisons were disclosed in the filing.

• ·SR Bancorp, Inc. is an emerging growth company listed on NASDAQ under ticker SRBK.
• ·Filing signed by Christopher J. Pribula, CEO, on March 19, 2026.

19-03-2026

Gemini Space Station, Inc. reported Q4 2025 total revenue of $60.3M, up 19% Q/Q and 39% Y/Y, marking the highest quarterly revenue in three years, driven by 33% Q/Q growth in services revenue to $26.5M which surpassed transaction revenue for the first time. However, trading volume declined 30% Q/Q to $11.5B and 25% Y/Y, card sign-ups fell 53% Q/Q to 30k, and assets on platform dropped 25% Q/Q to $15.9B. Full year 2025 revenue grew 26% Y/Y to $179.6M with services revenue up 115% Y/Y to $64.6M (44% of net revenue, +14ppt), though the company reduced workforce by 30% since early 2026 and exited UK, EU, and Australian markets to focus on the US.

• ·Received DCM license from CFTC to operate regulated prediction markets exchange.
• ·Added support for Monad, Tron, BSC, Hyperliquid, TON, SUI networks and over 20 new assets in past 12 months.
• ·Launched Gemini Wallet in H2 2025.
• ·Introduced spot margin trading with up to 5x leverage in January 2026.
• ·Q4 institutional revenue grew 30% Q/Q despite 32% volume decline.
• ·Retail fee economics at highest quarterly level in FY2025.
• ·IPO on September 12, 2025.
• ·Exited UK, EU, and Australian markets to focus on US.

19-03-2026

Zions Bancorporation, N.A.'s 2026 proxy statement outlines the annual shareholder meeting on May 1, 2026, proposing the election of 11 directors (82% independent), ratification of Ernst & Young LLP as auditors for fiscal 2026, and an advisory vote approving 2025 named executive officer compensation, while recommending against a shareholder proposal on risks from policy-customer misalignment. Governance highlights include 100% independent standing committee membership, 45% board diversity, average director age of 66 and tenure of 12.5 years, and a CEO pay ratio of 64:1. No significant declines or flat metrics noted in governance disclosures.

• ·Record date: March 2, 2026
• ·Annual meeting location: Zions Bank Building Founders Room, 18th Floor, One South Main Street, Salt Lake City, Utah 84133
• ·Average director tenure: 12.5 years
• ·Average director age: 66
• ·CEO pay ratio: 64:1
• ·Shareholder right to call special meeting: by holders of 51% of votes entitled to be cast

19-03-2026

GrowGeneration Corp. published a press release announcing its financial results for the fourth quarter and full year 2025, along with full year 2026 guidance. The Board of Directors also authorized a share repurchase program of up to $10M, which may commence after customary administrative and regulatory processes, subject to market conditions and legal requirements.

• ·Press release attached as Exhibit 99.1 and furnished, not filed, under Regulation FD.
• ·Information not deemed incorporated by reference in other filings.

19-03-2026

GENELUX Corp (GNLX) filed its 10-K on March 19, 2026, disclosing it has incurred significant losses since inception, generated no revenue from product sales, and anticipates continued increasing losses without achieving profitability. The company relies on its sole clinical-stage product candidate, Olvi-Vec, in Phase 3 trials for PRROC, but highlights substantial risks including need for additional financing, regulatory delays, manufacturing challenges, and high dependence on this single asset with no approved products. Forward-looking plans involve advancing trials, manufacturing expansion, and hiring, but emphasize uncertainties in commercialization and market acceptance.

• ·Never generated any revenue from commercially approved product sales
• ·Only one product candidate (Olvi-Vec) in clinical development
• ·Highly dependent on key personnel including President, Chief Executive Officer and Chairman

19-03-2026

AMERICAN BATTERY MATERIALS, INC. reported total assets of $396k as of Dec 31, 2025, up 23% YoY from $323k, driven by higher prepaid expenses, while cash plummeted 73% to $3k. The company posted a net loss of $6.4M for FY2025, worsening 49% YoY from $4.3M amid 19% higher operating expenses and increased other expenses; however, cash used in operations improved to $0.5M from $0.75M. Total liabilities surged 50% to $10.7M, deepening the stockholders' deficit to $10.3M from $6.8M.

• ·All 49,446 warrants expired during 2025.
• ·Weighted average common shares basic and diluted: 2,806,083 (FY2025) vs 2,377,691 (FY2024).
• ·Net loss per share: $(2.30) FY2025 vs $(1.81) FY2024.
• ·Convertible notes payable net: $5.6M (2025) up from $3.9M (2024).

19-03-2026

QUALCOMM Incorporated held its 2026 Annual Meeting of Stockholders on March 17, 2026, where all 11 director nominees were elected with strong majorities (FOR votes ranging from 696.9M to 747.6M), PricewaterhouseCoopers LLP was ratified as auditors for fiscal year ending September 27, 2026 (837.2M FOR), advisory approval of executive compensation passed (686.4M FOR), annual frequency for future votes was favored (737.6M for 1 year), and the Amended 2023 Long-Term Incentive Plan was approved including a 24M share reserve increase (700.1M FOR). However, two stockholder proposals failed: 'Shareholder Ability to Call for a Special Shareholder Meeting' (316.2M FOR vs. 432.7M AGAINST) and 'Report on Risk of China Exposure' (22.1M FOR vs. 722.0M AGAINST). Broker non-votes were consistent at 159.3M across proposals.

• ·Proxy statement dated January 22, 2026
• ·Some directors received significant WITHHOLD votes: Ann M. Livermore (53.2M), Irene B. Rosenfeld (54.7M), Jeffrey W. Henderson (37.7M)

19-03-2026

Enzon Pharmaceuticals, Inc. announced an extension of the expiration date for its exchange offer allowing holders of Series C Non-Convertible Redeemable Preferred Stock to exchange for common stock, now set to expire at 5:00 p.m. ET on March 24, 2026, unless further extended. This update is in connection with the proposed merger with Viskase Companies, Inc., for which a Form S-4 Registration Statement has been filed with the SEC. No financial metrics or performance changes were disclosed.

• ·Press release attached as Exhibit 99.1, incorporated by reference to Amendment No. 7 to Schedule TO-I/A filed March 19, 2026.
• ·Registration Statement on Form S-4 available at www.sec.gov and https://www.enzon.com.

19-03-2026

Armour Residential REIT, Inc. filed Definitive Additional Materials (DEFA14A) on March 19, 2026, as part of its proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials for the 2025 proxy. No financial metrics, performance data, or other substantive details are provided in the filing header.

19-03-2026

Ollie's Bargain Outlet Holdings, Inc. (OLLI) reported FY2025 net sales of $2.65B, up 16.6% YoY from $2.27B in FY2024, with gross profit increasing 17.3% to $1.07B and net income rising 20.4% to $241M. The company expanded aggressively, opening 86 new stores (vs. 50 prior year) to reach 645 total stores, while comparable store sales grew 3.7% (up from 2.8%). However, product category sales mix remained largely flat YoY, with Consumables steady at 31.9%, Seasonal down slightly to 19.1%, and average net sales per store up modestly 1.3% to $4.3M.

• ·Adjusted EBITDA grew 17.0% YoY to $366M from $313M.
• ·Pre-opening expenses increased to $25.3M from $19.3M.
• ·Company does not expect to pay cash dividends for the foreseeable future.
• ·Board authorized to issue up to 50M shares of undesignated preferred stock without stockholder approval.

19-03-2026

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a proposed public offering of shares of common stock (or equivalents) and warrants, with net proceeds intended to fund R&D activities including the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, alongside working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent. However, the offering is subject to market and other conditions, with no assurance as to completion, timing, size, or terms.

• ·Shelf registration statement on Form S-3 (File No. 333-276848) filed February 2, 2024, effective February 13, 2024.
• ·References risks in Form 10-K for year ended December 31, 2024, and 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025.

19-03-2026

Occidental Petroleum's 2026 Proxy Statement highlights robust 2025 performance with $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M reduction in capital and operating costs, record production, and company-record safety TRIR of 0.07, despite a more challenging commodity price environment YoY. Management reduced principal debt by $4B directly and an additional $7B via OxyChem divestiture proceeds, grew the resource base to 16.5B BOE from 8B in 2015, and increased dividends with a recent quarterly hike over 8% and 44% total rise since the 2023 CrownRock acquisition announcement. The annual meeting on May 1, 2026 seeks election of 10 directors, advisory approval of NEO compensation, and ratification of KPMG as auditor.

• ·Record date for annual meeting: March 10, 2026
• ·2026 Annual Meeting: May 1, 2026 at 9:00 a.m. Central Time via live webcast at www.virtualshareholdermeeting.com/OXY2026
• ·TRIR including OxyChem: 0.14 for FY 2025
• ·Proposals: Elect 10 directors, advisory vote on NEO compensation, ratify KPMG

19-03-2026

New Providence Acquisition Corp. III (NPACU), a SPAC, shared via social media on March 19, 2026, details of its proposed business combination with Abra Financial Holdings, Inc., pursuant to a Business Combination Agreement dated March 16, 2026, involving merger sub Aether Merger Sub I, Corp. The communication announces an upcoming Registration Statement on Form S-4, including a proxy statement/prospectus for SPAC shareholders, with standard advisories to review SEC filings for transaction details and risks. It emphasizes extensive forward-looking statement disclaimers and lists over 30 specific risks, including regulatory uncertainties in digital assets, potential failure to close, high transaction costs, and crypto market volatility.

• ·Commission File No.: 001-42610
• ·SPAC address: 401 S County Road #2588, Palm Beach, FL 33480
• ·IPO Prospectus filed with SEC on April 24, 2025

19-03-2026

Eton Pharmaceuticals, Inc. highlighted strengths in business development, regulatory expertise via the 505(b)(2) pathway, and established commercial operations in its 10-K filing. Cash flows showed strong improvement with net cash from operating activities rising to $10.5M in 2025 from $1.0M in 2024 (986% YoY increase), and net cash position up $11.0M; however, 2024 saw a large $40.0M investing outflow likely from acquisitions, operating cash declined 86% YoY in 2024 from 2023, and the filing details extensive risks including pricing pressures from the Inflation Reduction Act, regulatory hurdles, competition, and compliance issues.

• ·Team has completed over 150 business development transactions historically.
• ·Filing date: March 19, 2026

19-03-2026

FedEx reported strong revenue growth of 8% YoY to $24B in Q3 FY26 and 6% YoY to $69.7B for the nine months ended Feb 28, 2026, driving net income up 16% YoY to $1.06B quarterly and $2.84B YTD, with diluted EPS rising to $4.41 and $11.91 respectively. However, operating expenses increased across most categories including salaries (+12% YoY quarterly) and purchased transportation (+8% YoY), leading to a slight Q3 operating margin contraction to 5.6% from 5.8% prior year, while YTD margin expanded to 5.6% from 5.2%. Cash and equivalents surged to $8B from $5.5B at May 31, 2025, bolstered by $5.7B operating cash flow (up 25% YoY YTD).

• ·Separation and other costs rose to $202M in Q3 FY26 from $5M YoY.
• ·Business optimization costs declined to $65M in Q3 FY26 from $179M YoY.
• ·Long-term debt increased to $22.8B from $19.2B at May 31, 2025.
• ·Treasury stock repurchases totaled 3.3M shares YTD FY26 vs 8.9M prior year.

19-03-2026

Bar Harbor Bankshares' DEF 14A proxy statement for the 2026 Annual Meeting on May 7, 2026, seeks approval to elect 10 director nominees, approve on a non-binding advisory basis the compensation of named executive officers, and ratify Crowe LLP as the independent auditor for the fiscal year ending December 31, 2026. The CEO letter highlights successful navigation of economic challenges, expansion via the acquisition of Woodsville Guaranty Savings Bank, and a strong branch network exceeding 60 locations across Maine, New Hampshire, and Vermont as of December 31, 2025, with no notable declines mentioned. Director Kenneth Smith is retiring after over 20 years of service.

• ·Record Date: March 2, 2026
• ·Proxy materials mailed on or about March 16, 2026
• ·Voting deadlines: 11:59 p.m. EDT on May 6, 2026 (direct shares); May 4, 2026 (401(k) Plan shares)
• ·Annual Meeting location: Bar Harbor Club, 111 West Street, Bar Harbor, Maine
• ·James E. Graham joined Board in 2025 as former CEO of acquired Woodsville Guaranty Savings Bank

19-03-2026

Church & Dwight Co., Inc.'s 2026 Proxy Statement details the virtual annual stockholder meeting on May 1, 2026 at 12:00 p.m. EDT (record date March 4, 2026), seeking election of 11 director nominees (10 independent), advisory approval of named executive officer compensation, ratification of Deloitte & Touche LLP as 2026 auditors, and rejection of a stockholder proposal for written consent action. The Board, led by independent Chairman Ravichandra K. Saligram, highlights strong governance including majority voting, age 75 retirement policy, overboarding limits (4 public boards for non-employees, 2 for CEO), and 100% compliance with attendance (at least 75% of 2025 meetings). No performance declines or flat metrics are noted in the governance disclosures.

• ·Annual meeting virtual location: www.virtualshareholdermeeting.com/CHD2026
• ·Director retirement age limit: 75
• ·Overboarding limits: 4 public company boards for non-employee directors; 2 for CEO
• ·All directors in compliance with overboarding policy
• ·Filing date: March 19, 2026

19-03-2026

TTM Technologies, Inc. filed its DEF 14A Proxy Statement for the 2026 Annual Meeting on May 7, 2026 (virtual), seeking stockholder approval to elect three Class II directors (Julie S. England, Philip G. Franklin, Dr. Edwin Roks) for terms expiring in 2029, approve the Equity Advantage Match Plan, advisory approval of named executive officer compensation, a one-year frequency for future say-on-pay votes, and ratification of KPMG LLP as independent auditors for the fiscal year ending December 28, 2026. The record date is March 11, 2026. No specific financial performance metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Annual Meeting location: virtual via https://edge.media-server.com/mmc/p/hrz4mkaj (password: ttm2026)
• ·Fiscal year 2025 ended December 29, 2025 (referenced 2025 Form 10-K)
• ·Voting requirements: majority of votes cast for director elections; majority of shares present/entitled to vote for other proposals

19-03-2026

Independent Bank Corp. (INDB) filed an 8-K on March 19, 2026, announcing the declaration of a quarterly common stock dividend via press release (Exhibit 99.1). The filing was signed by Chief Financial Officer Mark J. Ruggiero. No specific dividend amount or financial metrics were detailed in the provided filing content.

• ·Filing items: 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits)
• ·Commission File Number: 0000776901
• ·I.R.S. Employer Identification No.: 04-2870273

19-03-2026

Star Bulk Carriers Corp. (SBLK) details its ESG performance in its 20-F annual report filed on March 19, 2026, highlighting fleet retrofits with scrubbers for IMO-2020 sulfur emissions compliance and implementation of the Ballast Water Management Convention across its entire fleet. The company monitors vessel performance for IMO's 2030 and 2050 GHG strategies using telemetry and data systems, participates in Poseidon Principles and Sea Cargo Charter, and engages in sustainability partnerships such as the Maritime Emissions Reduction Centre, Global Maritime Forum, Getting to Zero Coalition, Clean Shipping Alliance, and Hellenic Marine Environment Protection Association. It is also active in projects for green technologies, including voyage optimization platforms to reduce fuel consumption and CO2 footprint.

19-03-2026

Global Partners LP exercised the accordion feature of its Third Amended and Restated Credit Agreement to increase Aggregate WC Interim Commitments by $300M, effective March 13, 2026, for a maximum of 364 days after which it automatically reduces to $0. The Partnership also received lender approval to optionally reallocate up to $200M from Aggregate Revolver Commitment to Aggregate WC Commitments. All other material terms remain unchanged from those disclosed in the Form 10-K for the year ended December 31, 2025.

• ·Credit Agreement originally dated April 25, 2017
• ·Partnership acts as guarantor; certain subsidiaries as borrowers
• ·Aggregate WC Interim Commitment automatically reduces to $0 after 364 days

19-03-2026

Global Interactive Technologies, Inc. (GITS) announced the resignation of Juhyon Shin as Chief Financial Officer on December 22, 2025, with the company confirming no disagreements on financial reporting, accounting, or disclosure matters. Following the resignation, the Board approved engagement of an external financial consultant to lead preparation of financial statements and coordinate the ongoing audit process. The company continues efforts to complete and file its Annual Report on Form 10-K.

• ·Company headquartered at 160, Yeouiseo-ro, Yeongdeungpo-gu, Seoul, Republic of Korea 07231
• ·Common Stock trades on Nasdaq under symbol GITS, par value $0.001 per share
• ·Emerging growth company status

19-03-2026

Third Coast Bancshares, Inc. (TCBX) announced on March 19, 2026, that its Board of Directors declared a quarterly cash dividend of $16.875 per share on its 6.75% Series A Convertible Non-Cumulative Preferred Stock, payable on April 15, 2026, to holders of record at the close of business on March 31, 2026. The announcement was made via press release attached as Exhibit 99.1. No comparative financial metrics or performance data were provided.

19-03-2026

GEO Group Inc's DEF 14A proxy statement, filed March 19, 2026, outlines corporate governance practices, board self-assessments, shareholder engagement, and auditor fees, which declined 7.4% to $3.38M in 2025 from $3.65M in 2024, driven by a 6.0% drop in audit fees and elimination of $77K in other fees, while tax fees increased 5.0%. The filing includes pay versus performance disclosures with adjustments for equity awards, pension costs, and other metrics for multiple Principal Executive Officers (PEOs) including George C. Zoley, Jose Gordo, Brian Evans, and David Donahue across 2021-2025. Grant Thornton LLP was reappointed as independent auditors for 2026.

• ·All directors attended the 2025 annual shareholder meeting.
• ·GEO engages annually with approximately two dozen institutional investors holding more than 50% of outstanding common stock.
• ·Non-employee directors meet in executive session at least twice per year, presided by Lead Independent Director.
• ·Pay versus performance disclosures cover 2021-2025 with multiple PEOs and Non-PEO NEOs, including equity award fair value changes, vesting adjustments, and defined benefit plan costs.

19-03-2026

Better Home & Finance Holding Company's Audit Committee dismissed Deloitte & Touche LLP as its independent registered public accounting firm effective March 16, 2026, after a comprehensive selection process, with no disagreements or qualified audit opinions for fiscal years 2025 and 2024. The Company appointed BDO USA, P.C. as the new auditor for the fiscal year ending December 31, 2026, following execution of an engagement letter on March 18, 2026. While prior material weaknesses in internal controls (disclosed in 2024 10-K) were remediated by December 31, 2025, the change reflects a routine auditor rotation with Deloitte's concurrence via letter dated March 19, 2026.

• ·Deloitte served as auditor since 2020.
• ·Warrants exercisable at $575 per share of Class A common stock.
• ·No consultations with BDO on accounting or auditing matters prior to appointment.

19-03-2026

The Gabelli Global Small & Mid Cap Value Trust (GGZ) has filed a definitive proxy statement (DEF 14A) for its Annual Meeting of Shareholders on May 11, 2026, at 8:45 a.m. ET, to elect three Trustees—Mario J. Gabelli, James P. Conn, and Salvatore J. Zizza—for terms expiring at the 2029 Annual Meeting. As of the record date March 12, 2026, 7,640,349 Common Shares and 4,000,000 5.20% Series E Cumulative Preferred Shares were outstanding, with GAMCO Investors, Inc. and affiliates holding 36.8% of Common Shares and 49.5% of Preferred Shares. No dividend arrearages on Preferred Shares were reported, and the Board consists of nine Trustees, with Common and Preferred shareholders voting together as a single class for these nominees.

• ·Quorum requires holders of one-third of outstanding shares entitled to vote.
• ·Preferred shareholders elect two Trustees separately (currently Frank J. Fahrenkopf, Jr. and John Birch).
• ·No dividend arrearages on Preferred Shares as of proxy statement date.
• ·Proxy solicitation costs borne by the Fund, with reimbursement to brokers.